Suven Life Sciences Limited (SUVEN) completes patient enrollment in global Phase-3 study of Masupirdine for agitation associated with Alzheimer’s Dementia.
Suven Life Sciences Limited (SUVEN) to showcase its CNS clinical candidates and partnering strategies at BIO International Convention 2026 in San Diego.
Suven Life Sciences Limited reaches 76% enrollment in its Global Phase 3 Masupirdine trial for Alzheimer’s agitation.